How much does a bottle of tazitaxel cost in China? Interpretation of the latest prices and medical insurance policies

Tazemetostat As a newEZH2 inhibitor, it has been gradually promoted globally in recent years, and its launch in China has attracted widespread attention. Since the drug is mainly used to treat relapsed or refractory follicular lymphoma (FL; non-Hodgkin lymphoma) and epithelioid sarcoma (ES; soft tissue sarcoma), its high price and medical insurance policy have become the focus of attention of patients. At present, tazerestat has been approved in China, but it has been on the market for a short time, so the market price and medical insurance reimbursement policy are not yet completely clear.

According to the international market price, the price of tazerestat is relatively expensive. Taking the U.S. market as an example, the original version of the drug is developed and sold by Epizyme. The price of 200mg*56 capsules is usually around 25,000 to 30,000 yuan. Prices in the Japanese market are similar to those in the United States, but may fluctuate slightly due to regional differences and import costs. In mainland China, although the drug has been approved, the official pricing has not yet been fully announced. Prior to this, many patients obtained the drug through cross-border drug purchase or overseas medical channels, such as purchasing it from regular pharmacies in the United States, Japan, India, Laos and other places.

Because patients are price-sensitive, the generic drug market also offers relatively economical options. For example, the Lao version of tazerestat is produced by a well-known local pharmaceutical company. It has the same specifications as the original drug (200mg*56 tablets) and is priced at approximately RMB 4,000 to 5,000 yuan. Compared with the original drug, the cost is significantly reduced, making it more affordable for more patients. However, it should be noted that although the active ingredients of generic drugs and original drugs are basically the same, there may be certain differences in production processes, quality control and bioequivalence. Therefore, patients should consult a professional doctor when making a choice to ensure safety and efficacy.

In terms of medical insurance policy, tazetostat has not yet been included in China's national medical insurance catalog, but with its promotion in the domestic market, it may enter the scope of medical insurance negotiations in the future. Once included in medical insurance, the price of the drug may drop and the financial burden on patients will be reduced through a reimbursement mechanism.

Reference materials:https://www.tazverik.com/